enVVeno Medical Corp (NVNO) - Dilution Analysis

10-Q filing | 0.7M shares outstanding

10-K filing | 0.7M shares outstanding

8-K filing: Stock split 1-for-35 | Outstanding: 20,155,000 → 655,606

10-Q filing | 20.2M shares outstanding

10-Q filing | 20.4M shares outstanding

10-Q filing | 17.5M shares outstanding

S-3/A filing: The filing is an S-3/A from ENVVENO MEDICAL CORPORATION for a shelf offering of common stock, preferred stock, purchase contracts, subscription rights, depositary shares, and debt securities, with a total gross proceeds of up to $100,000,000.

S-3 filing: ENVVENO MEDICAL CORPORATION files an S-3 for offering common stock, preferred stock, purchase contracts, subscription rights, depositary shares, and debt securities for total gross proceeds of up to $100,000,000.

10-K filing | 17.1M shares outstanding

10-Q filing | 16.1M shares outstanding

8-K filing: enVVeno Medical Corporation closed a public offering of common stock and pre-funded warrants for gross proceeds of approximately $15 million. ($14.98M proceeds)

10-Q filing | 13.3M shares outstanding

10-Q filing | 13.3M shares outstanding

10-K filing | 12.3M shares outstanding

S-3 filing: This S-3 filing relates to the resale by selling stockholders of up to 14,708,942 shares of common stock of enVVeno Medical Corporation.

10-Q filing | 13.3M shares outstanding

8-K filing: enVVeno Medical Corporation sold 3,844,704 shares of common stock and Pre-Funded Warrants to purchase 977,900 shares, along with Tranche A and B warrants to purchase 4,822,604 shares each, to certain institutional investors, raising approximately $28 million in gross proceeds, which closed on October 11, 2023. ($28.0M proceeds)

S-3/A filing: Envveno Medical Corporation files an S-3/A form for a shelf offering of common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares and debt securities, for total gross proceeds of up to $75,000,000.

10-Q filing | 9.5M shares outstanding

S-3 filing: Envveno Medical Corporation files an S-3 form to register an offering of common stock, preferred stock, purchase contracts, subscription rights, depositary shares, and debt securities for total gross proceeds of up to $75,000,000.

10-Q filing | 9.5M shares outstanding

10-K filing | 9.5M shares outstanding

10-Q filing | 9.5M shares outstanding

10-Q filing | 9.5M shares outstanding

10-Q filing | 9.5M shares outstanding

10-K filing | 9.5M shares outstanding

10-Q filing | 9.5M shares outstanding

8-K filing: Hancock Jaffe Laboratories, Inc. entered into a Securities Purchase Agreement with Perceptive Advisors for approximately $20 million in gross proceeds, involving the sale of 781,615 shares of common stock at $7.872 per share and Pre-Funded Warrants to purchase 1,759,035 shares at $7.8719 per Pre-Funded Warrant.

10-Q filing | 8.5M shares outstanding

10-Q filing | 2.5M shares outstanding

POS AM filing: This prospectus relates to the primary issuance by the Company of up to 3,604,594 shares of common stock and the resale of up to 1,023,668 shares of common stock held by certain selling stockholders.

10-K filing | 0.7M shares outstanding

8-K filing: Hancock Jaffe Laboratories, Inc. closed a firm commitment public offering of its securities for gross proceeds of approximately $41.4 million, including the exercise in full and closing of the over-allotment option granted to the underwriters. ($41.4M proceeds)

S-1/A filing: This S-1/A filing relates to an offering of units, each consisting of one share of common stock and one warrant to purchase one-half of a share of common stock, at a price of $9.31 per unit, as well as the shares of common stock issuable upon exercise of the warrants.

S-1/A filing: This S-1/A filing registers 3,222,341 units consisting of shares of common stock and warrants to purchase common stock.

S-1/A filing: This S-1/A filing relates to an offering of units, each consisting of one share of common stock and one-half warrant to purchase one-half of a share of common stock, at a price of $9.31 per unit, along with the shares of common stock issuable upon exercise of the warrants.

S-1 filing: This S-1 filing describes an offering of Units consisting of Shares of Common Stock and Warrants to Purchase Shares of Common Stock, with a strategic investor indicating interest in purchasing up to $10,000,000 units.

8-K filing: Stock split 1-for-25 | Outstanding: 17,931,857 → 2,234,143

S-1/A filing: This S-1/A filing registers for resale 15,610,834 shares of common stock, including shares issuable upon exercise of warrants and shares issued in exchange for convertible preferred stock.

8-K filing: Hancock Jaffe Laboratories, Inc. exchanged 4,205,406 shares of its Series C Convertible Preferred Stock for 6,078,125 shares of common stock on November 24, 2020.

10-Q filing | 17.9M shares outstanding

S-1 filing: This prospectus relates to the resale of up to 9,532,709 shares of common stock, par value $0.00001 per share, of Hancock Jaffe Laboratories, Inc. issuable upon exercise of the warrants to purchase shares of common stock at an exercise price of $0.41 per share.

8-K filing: Hancock Jaffe Laboratories, Inc. entered into a Securities Purchase Agreement to sell 9,532,709 shares of common stock and warrants to purchase 9,532,709 shares of common stock for gross proceeds of approximately $5.1 million. ($5.1M proceeds)

S-3/A filing: This prospectus relates to the resale by selling stockholders of up to 17,081,250 shares of common stock of Hancock Jaffe Laboratories, Inc.

S-3 filing: This S-3 filing relates to the resale of up to 17,033,529 shares of common stock by selling stockholders of Hancock Jaffe Laboratories, Inc.

10-Q filing | 17.9M shares outstanding

8-K filing: Hancock Jaffe Laboratories, Inc. completed a public offering of 14,375,000 shares of common stock and warrants, along with a concurrent private placement of Series C Convertible Preferred Stock and warrants, resulting in net proceeds of approximately $5.2 million. ($6.16M proceeds)

S-1/A filing: The company is offering 10,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock at a price per unit of $0.40. Additionally, in a concurrent private placement, they are offering Series C Convertible Preferred Stock and unregistered warrants.

S-1/A filing: The filing relates to an offering of 10,000,000 units, with each unit consisting of one share of common stock and one-half warrant to purchase one-half share of common stock, at a price per unit of $0.40.

S-1 filing: This S-1 filing describes an offering of units consisting of shares of common stock and warrants to purchase shares of common stock.

S-1 filing: This S-1 filing relates to the primary issuance by the Company of up to 1,811,250 shares of common stock and the resale of up to 9,980,759 shares of common stock held by certain selling stockholders.

10-Q filing | 17.9M shares outstanding

8-K filing: Hancock Jaffe Laboratories, Inc. sold 2,930,402 shares of common stock at $0.33 per share and warrants to purchase up to 2,930,402 shares at $0.125 per warrant in a registered direct offering and concurrent private placement for gross proceeds of approximately $1.333 million. ($0.0M proceeds)

8-K filing: Hancock Jaffe Laboratories, Inc. sold 1,886,793 shares of common stock at $0.405 per share and warrants to purchase up to 1,886,793 shares of common stock at $0.125 per warrant in a registered direct offering and concurrent private placement for gross proceeds of approximately $1.0 million.

S-3 filing: The Registrant is registering an indeterminate aggregate principal amount and number of securities of each identified class of securities up to a proposed aggregate offering price of $75,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issuable upon conversion, redemption, repurchase, exchange, or exercise of any securities registered hereunder, including under any applicable anti-dilution provisions.

10-K filing | 11.7M shares outstanding

8-K filing: Hancock Jaffe Laboratories, Inc. raised $650,000 in gross proceeds through a private placement bridge offering, selling 1,300,000 shares of common stock and warrants to purchase 1,300,000 shares of common stock. ($0.65M proceeds)